Interaction Checker
Do Not Coadminister
Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF)
Fluticasone
Quality of Evidence: Moderate
Summary:
Coadministration has not been studied. Concomitant use of elvitegravir/cobicistat and glucocorticoids metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression. Alternative corticosteroids should be considered, particularly for long term use. Systemic corticosteroid effects have been reported in patients receiving strong inhibitors of CYP3A4 and inhaled or intranasally administered fluticasone propionate. A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g. beclometasone). Moreover, in case of withdrawal of glucocorticoids progressive dose reduction may have to be performed over a longer period. Emtricitabine and tenofovir alafenamide are unlikely to interact with fluticasone.
Description:
View all available interactions with Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF) by clicking here.
Copyright © 2024 The University of Liverpool. All rights reserved.